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December 20121810 Abstractspossible that aneurysms discovered incidentally may be detected when a
higher proportion are potentially treated by EVAR. In addition, comorbidi-
ties in patients with incidentally discovered AAAs may be different than in
those whose AAAs were discovered on physical examination or were associ-
ated with symptoms. TheMedicare database also does not examine the effect
of decreasing smoking rates on overall AAA-related mortality. It is very
probable there are epidemiologic and procedurally related, as well as sociality
related factors, that are all contributing to a decline of mortality related to
AAA.
Common Carotid Intima-Media Thickness Measurements in Cardio-
vascular Risk Prediction: A Meta-Analysis
den Ruijter HM, Peters SA, Anderson TJ, et al. JAMA 2012;308:796-803.
Conclusion: When added to the Framingham Risk Prediction Score,
the addition of common carotid intima-media thickness (CIMT) measure-
ments only minimally improves 10-year risk prediction of first-time myocar-
dial infraction or stroke. This improvement is unlikely to be of clinical
importance.
Summary: Prediction of cardiovascular risk is a moving target. Cardio-
vascular risk prediction for asymptomatic subjects is currently performed by
incorporating risk factors into some sort of scoring equation (Berger JS, et al,
J Am Coll Cardiol 2010;55:1169-77). Of these scoring equations, the
Framingham Risk Score is among the most widely used (D’Agostino RB Sr,
et al, Circulation 2008;117:743-53). However, prediction of cardiovascular
risk with risk equations, while reasonably accurate, still needs considerable
improvement with regard to sensitivity and specificity. Hence, there is a
desire to incorporate additional risk predictors into risk score equations. One
of these potential additional predictors to improve individual cardiovascular
risk assessments has been CIMT. The current article reports a meta-analysis
of the use CIMT to determine what value CIMT adds to current risk
predictionmodels in asymptomatic patients at risk for cardiovascular disease.
The specific goal was to determine whether common carotid CIMT had
added value in 10-year risk prediction of first time myocardial infarction or
stroke above that of the Framingham Risk Score alone. The authors identi-
fied relevant studies through literature searches of databases (PubMed from
1950-June 2012 and EMBASE from 1980-June 2012) and through expert
opinion. To be included, studies must have had participants drawn from the
general population, had participants with CIMT measured at baseline, and
the individuals had to have been followed up for first time myocardial
infarction or stroke. The authors included 14 population-based cohort
studies contributing data from 45,828 individuals. Median follow-up was 11
years, during which were 4,007 first time myocardial infarctions or strokes.
The authors fitted the risk factors of the Framingham Risk Score and then
extended the model with common carotid CIMTmeasurements to estimate
absolute 10-year risks to develop a first time myocardial infarction or stroke
in both models. The C statistic of both models was similar at 0.757 (95%
confidence interval [CI], 0.749-0.764) and 0.759 (95% CI 0.752-0.766).
Net reclassification improvement with the addition of common CIMT
carotid was small (0.8%; 95% CI, 0.1%-1.6%) in patients at intermediate risk.
Net reclassification improvement was 3.6% in all individuals (95% CI,
2.7%-4.6%). There were no differences between men and women.
Comment: One must agree with the authors that the apparent mag-
nitude of benefit of adding CIMT measurements as a measure of cardiovas-
cular risk in the general population, even in patients at intermediate risk, is
unlikely to be of any significant clinical benefit at 10 years. Advocates of
CIMT measurements should point out 10 years in an asymptomatic or
low-risk population is still a relatively short period of time. It is still possible
CIMT measurements may be of some benefit if the time line is extended to
20, 30, or even more years. It also should be noted that most of the patients
analyzed in this data were Caucasian, and therefore, the data cannot be
precisely extrapolated to non-Caucasian populations. Nevertheless, despite
intense interest for many years, there still does not appear to be convincing
data that measurement of CIMT has any practical use in the day-to-day care
of patients.
Antiplatelet Drug Response Status Does Not Predict Recurrent Isch-
emic Events in Stable Cardiovascular Patients Results of the Antiplate-
let Drug Resistances and Ischemic Events Study
Reny JL, Berdague P, Poncet A, and the Antiplatelet Drug Resistances and
Ischemic Events (ADRIE) Study Group. Circulation 2012;125:3201-10.
Conclusion: For stable outpatients with cardiovascular disease, mea-
surements of antiplatelet drug responsiveness with aggregation-based assays
or specific assays have no incremental predictive value over assessment of
standard cardiovascular risk factors for recurrent major adverse cardiovascu-
lar events (MACE).
Summary: Aspirin permanently inactivates cyclooxygenase-1, with
subsequent inhibition of thromboxane A2 production. Other antiplatelet
drugs, such as clopidogrel, target platelet adenosine diphosphate amplifica-
tion through inhibition of P2Y12 receptor function. Patient responsiveness
to antiplatelet drugs is variable andmay influence cardiovascular outcomes in
a
batients treated with aspirin or clopidogrel. It has been suggested that
ssessment of the biologic function of antiplatelet drugs could be used to
uide treatment in patients with cardiovascular disease. To date, however,
he value of specific and less specific platelet function assays to predict future
ardiovascular events in patients with cardiovascular disease has not been
ssessed. The authors sought to determine the added predictive value of
pecific assays (the vasodilator phosphoprotein assay for the clopidogrel
esponse and serum thromboxane B2 for aspirin response) and aggregation-
ased assays for future cardiovascular events relative to standard predictors of
ardiovascular risk. The authors twice tested 771 stable cardiovascular
utpatients participating in the Antiplatelet Drug Resistances and Ischemic
vents (ADRIE) study. Patients were tested with specific and aggregation-
ased assays. Follow-up lasted 3 years, and 1% of patients were lost to
ollow-up. MACE were assessed during follow-up and adjudicated by an
ndependent committee. Multivariant survival analysis used relevant vari-
bles identified in univariate analysis and platelet function test results. The
rognostic value of various multivariable models was expressed with the C
ndex. The primary end point was occurrence of MACE, and MACE
ccurred in 16% of patients. Hypertension, smoking, increased age, and
levated low-density lipoprotein cholesterol were predictive of MACE oc-
urrence. The C index was 0.63 (P .001). Specific and aggregation-based
ssays of platelet function did not add significant predictive value for the
rimary end point.
Comment: Previous studies have suggested a poor biologic response to
ntiplatelet drugs can be associated with recurrence of ischemic events. The
tudy population here was different than previous studies that included acute
atients assessed early on for platelet reactivity, usually 1 month after
tarting therapy. These previous studies suggested assessment of platelet
unction might be of value in the acute patient with a cardiovascular event.
he current study, however, does not support routine platelet testing in
table cardiovascular outpatients. Assessment of standard cardiovascular risk
actors remains the standard.
egional Versus General Anesthesia for Carotid Endarterectomy: The
merican College of Surgeons National Surgical Quality Improvement
rogram Perspective
chechter MA, Shortell CK, Scarborough JE. Surgery 2012;152:309-14.
Conclusion: The type of anesthesia technique does not impact patient
utcomes after carotid endarterectomy but may influence cost of care.
Summary: The advantages and disadvantages of regional vs general
nesthesia for carotid endarterectomy continue to be debated. Some inves-
igators have found regional anesthesia associated with lower postoperative
orbidity or mortality, or both, than general anesthesia. Such studies have
een hampered by small sample size and usually retrospective analysis. The
nly large multicenter randomized controlled trial to compare general
nesthesia with regional anesthesia for carotid endarterectomy, the GALA
rial, found no difference in regional vs general anesthesia on postoperative
utcomes in carotid endarterectomy (Louis SC, et al, Lancet 2008;372:
132-42). The current article represents a slightly different approach to
nalysis of this problem and used the National Surgical Quality Improve-
ent Program (NSQIP) database in an attempt to assess the effects of
egional vs local anesthesia on outcomes of carotid endarterectomy. The
uthors compared postoperative outcomes for the American College of
urgeons NSQIP database for patients undergoing carotid endarterectomy
etween 2005 and 2009 with respect to general or regional anesthesia. They
reformed a separate analysis using a subset of propensity-matched patients.
here were 24,716 patients in the NSQIP sample who underwent carotid
ndarterectomy. The propensity-matched cohort consisted of 8050 pa-
ients. The authors found no difference in 30-day postoperative composite
ates of stroke/myocardial infarction/death based on anesthetic type. With
he matched cohort, complications also did not differ (2.8% regional vs 3.6%
eneral; P  .07). Patients receiving regional anesthesia had shorter opera-
ive times (99  36 vs 119  53 minutes; P  .001) and shorter anesthesia
imes (52 29 vs 64 37 minutes; P .001). Regional anesthetic patients
ere also more likely to be discharged the next day (77.0% vs 64.4%; P 
001).
Comment:This report really doesn’t settle the issue of regional vs local
nesthesia on outcomes after carotid endarterectomy. As the authors point
ut in their discussion, despite the use of propensity analysis, there may be
nstated variables within the NSQIP database that influence the choice of
egional vs local anesthesia and that may influence outcomes after carotid
ndarterectomy. In addition, although the data suggest regional anesthesia
s not likely to be more expensive than general anesthesia for carotid
ndarterectomy, given the limitations of the NSQIP database, it also cannot
e used to definitely state that regional anesthesia will result in overall
ecreased cost for carotid endarterectomy. The study provides some infor-
ation regarding outcomes of carotid endarterectomy from the NSQIP
atabase. However, NSQIP is not designed to investigate costs or the effects
f anesthetic type on surgical procedures. It is therefore not surprising that
n analysis of a database that was not designed to answer the questions posed
y the authors did not provide a definitive answer to the authors’ question.
